Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 4/20 | 0.42 |
| ▸ | FNTB | P49356 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17482013 | 0.92 | MEN1 (0.54) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL17356858 | 0.84 | MAPT (0.51) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL17356861 | 0.82 | MAPT (0.49) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL17356845 | 0.82 | MAPT (0.74) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL7125015 | 0.81 | MEN1 (0.62) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL16156849 | 0.81 | MEN1 (0.62) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL15237167 | 0.78 | DRD3 (0.45) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL179882 | 0.77 | MEN1 (1.00) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL31014072 | 0.77 | MEN1 (1.00) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL13212466 | 0.76 | DRD3 (0.49) | MEN1KMT2ALMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | KCNJ2, KCNK2, KCNN3 | MEN1 4246/4885KMT2A 449/4885LMNA 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.